http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013302925-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
| filingDate | 2013-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18a65c1eaf6420215fdbe7055d8bcfd5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c27a502979842791cfacf4b0773cde7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_973ff7ce33b9c5f730a90445e1a94cfb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71e8bc575a50e2e40d5fbcaac5f3317e |
| publicationDate | 2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2013302925-B2 |
| titleOfInvention | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
| abstract | The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (PCSK9) with greater affinity at neutral pH than at acidic pH. The antibodies disclosed herein may possess one or more amino acid changes as compared to antibodies that do not exhibit pH-dependent binding properties. For example, the present disclosure includes anti-PCSK9 antibodies which possess one or more histidine substitutions in one or more complementarity determining regions. The antibodies disclosed herein, with pH-dependent binding properties, remain in circulation and exhibit cholesterol lowering activity for prolonged periods of time in animal subjects as compared to anti-PCSK9 antibodies that do not exhibit pH-dependent binding properties. The antibodies disclosed herein are therefore useful for treating diseases and disorders related to elevated HDL cholesterol, wherein the antibodiesdisclosed herein can be administered to a patient at a lower dose and/or with less frequent dosing as compared to antibodies that do not exhibit pH- dependent binding properties. |
| priorityDate | 2012-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 911.